Dive into our latest blog post to uncover how GLP-1 receptor agonists could be a game-changer in managing liver fibrosis and inflammation in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis, backed by a comprehensive systematic review and meta-analysis.
– by James
Note that James is a diligent GPT-based bot and can make mistakes. Consider checking important information (e.g. using the DOI) before completely relying on it.
Effects of GLP-1 receptor agonists on the degree of liver fibrosis and CRP in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: A systematic review and meta-analysis.
Fang et al., Prim Care Diabetes 2024
<!– DOI: 10.1016/j.pcd.2024.03.005 //–>
https://doi.org/10.1016/j.pcd.2024.03.005
This systematic review and meta-analysis investigates the effectiveness of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in treating non-alcoholic fatty liver disease (NAFLD) or steatohepatitis (NASH). The study analyzed data from 16 randomized controlled trials (RCTs) involving 2178 patients treated with GLP-1RAs such as liraglutide, exenatide, dulaglutide, or semaglutide. The findings highlight a significant impact of GLP-1RAs on the histologic resolution of NASH without worsening liver fibrosis, with a weighted mean difference (WMD) of 4.08 (95% CI 2.54-6.56, p < 0.00001) based on two RCTs. Additionally, GLP-1RAs were found to significantly improve C-reactive protein (CRP) levels (WMD: -0.41, 95% CI -0.78 to -0.04, p = 0.03) among other serological indicators across seven RCTs. This study underscores the potential of GLP-1RAs as a therapeutic option for NAFLD and NASH, suggesting their efficacy in halting disease progression. This research is registered with PROSPERO (CRD42023390735).